66 related articles for article (PubMed ID: 10815861)
1. Paraneoplastic pemphigus: a clinical, laboratorial, and therapeutic overview.
Maruta CW; Miyamoto D; Aoki V; Carvalho RGR; Cunha BM; Santi CG
An Bras Dermatol; 2019; 94(4):388-398. PubMed ID: 31644609
[TBL] [Abstract][Full Text] [Related]
2. Skin Barrier and Autoimmunity-Mechanisms and Novel Therapeutic Approaches for Autoimmune Blistering Diseases of the Skin.
Stevens NE; Cowin AJ; Kopecki Z
Front Immunol; 2019; 10():1089. PubMed ID: 31156638
[TBL] [Abstract][Full Text] [Related]
3. A Systematic Review of Patients with Mucocutaneous and Respiratory Complications in Paraneoplastic Autoimmune Multiorgan Syndrome: Castleman's Disease is the Predominant Malignancy.
Lee J; Bloom R; Amber KT
Lung; 2015 Aug; 193(4):593-6. PubMed ID: 25903794
[TBL] [Abstract][Full Text] [Related]
4. The diagnosis and treatment of autoimmune blistering skin diseases.
Schmidt E; Zillikens D
Dtsch Arztebl Int; 2011 Jun; 108(23):399-405, I-III. PubMed ID: 21712975
[TBL] [Abstract][Full Text] [Related]
5. Immunological hotspots analyzed by docking simulations: evidence for a general mechanism in pemphigus vulgaris pathology and transformation.
Tong JC; Sinha AA
BMC Immunol; 2008 Jun; 9():30. PubMed ID: 18564435
[TBL] [Abstract][Full Text] [Related]
6. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure?
Burt RK; Slavin S; Burns WH; Marmont AM
Int J Hematol; 2002 Aug; 76 Suppl 1():226-47. PubMed ID: 12430858
[TBL] [Abstract][Full Text] [Related]
7. Autoantibodies to type VII collagen have heterogeneous subclass and light chain compositions and their complement-activating capacities do not correlate with the inflammatory clinical phenotype.
Gandhi K; Chen M; Aasi S; Lapiere JC; Woodley DT; Chan LS
J Clin Immunol; 2000 Nov; 20(6):416-23. PubMed ID: 11202231
[TBL] [Abstract][Full Text] [Related]
8. Paraneoplastic pemphigus: a brief update.
Wade MS; Black MM
Australas J Dermatol; 2005 Feb; 46(1):1-8; quiz 9-10. PubMed ID: 15670168
[TBL] [Abstract][Full Text] [Related]
9. Epitope spreading in paraneoplastic pemphigus: autoimmune induction in antibody-mediated blistering skin diseases.
Chan LS
Arch Dermatol; 2000 May; 136(5):663-4. PubMed ID: 10815861
[No Abstract] [Full Text] [Related]
10. Lichenoid dermatitis in paraneoplastic pemphigus: a pathogenic trigger of epitope spreading?
Bowen GM; Peters NT; Fivenson DP; Su LD; Nousari HC; Anhalt GJ; Cooper KD; Stevens SR
Arch Dermatol; 2000 May; 136(5):652-6. PubMed ID: 10815859
[TBL] [Abstract][Full Text] [Related]
11. Paraneoplastic pemphigus is a distinct neoplasia-induced autoimmune disease.
Camisa C; Helm TN
Arch Dermatol; 1993 Jul; 129(7):883-6. PubMed ID: 8323311
[No Abstract] [Full Text] [Related]
12. Making sense of antigens and antibodies in pemphigus.
Anhalt GJ
J Am Acad Dermatol; 1999 May; 40(5 Pt 1):763-6. PubMed ID: 10321608
[No Abstract] [Full Text] [Related]
13. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus.
Nguyen VT; Ndoye A; Bassler KD; Shultz LD; Shields MC; Ruben BS; Webber RJ; Pittelkow MR; Lynch PJ; Grando SA
Arch Dermatol; 2001 Feb; 137(2):193-206. PubMed ID: 11176692
[TBL] [Abstract][Full Text] [Related]
14. [Auto-immune bullous diseases autoantibodies (pemphigus, bullous pemphigoid): what the dermatologist must know].
Ingen-Housz-Oro S; Hüe S; Grootenboer-Mignot S; André C
Ann Dermatol Venereol; 2013; 140(8-9):563-70. PubMed ID: 24034645
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
